Fundraising FoxBay City Capital — 2019 Investments
1 investments dated 2019 · listed companies and verified rows first · show all
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)
Board seatCarl Goldfischer· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)Pfizer Venture InvestmentsRA CapitalAlexandriaArix BioscienceJMI Equity+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.